Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities.

The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic’s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap’s own R&D efforts by utilizing Epic’s strengths in the manufacture and development of controlled drug substances and powder formulations. The Epic acquisition will also add a U.S. FDA & DEA inspected GMP manufacturing footprint of 110,000 square feet in Laurelton, NY, and result in the addition of 215 employees to the Humanwell and PuraCap U.S. operations team.

“This acquisition continues to broaden our global investments consistent with our strategy for the creation of a truly global pharmaceutical company for Humanwell Healthcare Group,” said Richard Wang, chairman, Humanwell Healthcare Group.

“This acquisition is a major step in the growth of our company. In addition to strong and growing OTC and branded business units in the U.S., this acquisition along with our recent acquisition of Blu Pharmaceutical and Blu Carib, firmly establishes Humanwell and PuraCap in the U.S. generic Rx pharmaceutical segment. “The PuraCap U.S. footprint continues to expand our tablet, softgel, 2-piece capsules, cream, and powder product portfolio,” said Dahai Guo, chief executive officer, PuraCap and president, Humanwell USA.